Jump to main content.

Bromate Quickview (CASRN 15541-45-4)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Bromate

File First On-Line: 06/06/2001; Last Significant Revision: 06/06/2001

Category (section)
Last Revised
Oral RfD Assessment Yes 06/06/2001
Inhalation RfC Assessment Discussion 06/06/2001
Carcinogenicity Assessment Yes 06/06/2001
  • Bromate
  • 15541-45-4
  • Bromate(1-), bromochloro-, rubidium
  • Bromic acid, potassium salt
  • Bromic acid, sodium salt
  • Bromic acid, zinc salt
Bromate Source Documents
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Renal effects: urothelial hyperplasia NOAEL : 1.1 mg/kg-day 300 4 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Information reviewed but value not estimated. See IRIS Summary.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)
    • Carcinogenic potential cannot be determined (Inhalation route)
    • Known/likely human carcinogen (Oral route)
  • Weight-of-Evidence Narrative:
    • Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Oral Slope Factor(s)
Extrapolation Method
7 x10-1 per mg/kg-day Time-to-tumor, Weibull
Drinking Water Unit Risks
2x10-5 per µg/L
Risk Level
E-4 (1 in 10,000) 5 µg/L
E-5 (1 in 100,000) 5x10-1 µg/L
E-6 (1 in 1,000,000) 5x10-2 µg/L
  • Dose-Response Data (Carcinogenicity, Oral Exposure)
    • Tumor Type: Testicular mesothelioma, renal tubular adenoma and carcinoma, and thyroid follicular cell adenoma and carcinoma
    • Test Species: F344 rats, male
    • Route: Oral, Drinking water
    • Reference: DeAngelo et al., 1998

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Information reviewed but value not estimated. See IRIS Summary.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.